Notably, they revealed that in North American men, who had much higher baseline use of PDE5 inhibitors, this treatment was associated with an inverse trend of prostate cancer diagnosis, but did not reach statistical significance (120). The gene discussed is PDE5A; the disease is Familial prostate cancer.